Marvel Biosciences closes private placement, raises $1,598,144.70 in gross proceeds

• Marvel Biosciences closed a non-brokered private placement, issuing 10,654,298 units at $0.15 for gross proceeds of $1,598,144.70.
• Each unit includes one common share, one warrant exercisable at $0.20, starting 61 days post-close for one year.
• Warrant expiry can be accelerated if the TSXV 5-day VWAP reaches at least $0.25, with at least 30 days’ notice.
• Net proceeds earmarked for a Phase 1 clinical-trial deposit for MB-204, general and administrative costs, working capital.
• Finders received $77,175.49 cash commission, 494,737 finder’s warrants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marvel Biosciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609291752NEWSFILECNPR____20260929_316696_1) on September 29, 2026, and is solely responsible for the information contained therein.